Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C

Open Forum Infectious Diseases

Volumn 1, Issue 3, 2014, Pages

  O'Brien, Thomas R ^a   Lang Kuhs, Krystle A ^a   Pfeiffer, Ruth M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical trial; Cost effectiveness; Direct acting antiviral agents; Gender; Hepatitis C virus; IFNL4

Indexed keywords

LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SOFOSBUVIR;

ADULT; ARTICLE; CHRONIC HEPATITIS C; CLINICAL TRIAL (TOPIC); DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE; GENOTYPE; HEALTH CARE COST; HUMAN; IFNL4 GENE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84978328245     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu110     Document Type: Article

References (15)

1. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-88.
2. Hoofnagle JH, Sherker AH. Therapy for hepatitis C-the costs of success. N Engl J Med 2014; 370:1552-3.
3. Alshurafa M, Briel M, Akl EA, et al. Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One 2012; 7:e49163.
4. White IR, Horton NJ, Carpenter J, et al. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ 2011; 342:d40.
5. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369:630-9.
6. Tseng FC, Edlin BR, Zhang M, et al. The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use. J Viral Hepat 2008; 15:690-8.
7. Villa E, Karampatou A, Cammà C, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011; 140:818-29.e2.
8. Meissner EG, Bon D, Prokunina-Olsson L, et al. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 2014; 209:1700-4.
9. Prokunina-Olsson L, Muchmore B, TangW, et al. Avariant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45:164-71.
10. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
11. O'Brien TR, Prokunina-Olsson L, Donnelly RP. IFN-λ4: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res 2014; 34:829-38.
12. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
13. Meissner EG, Nelson A, Marti M, et al. Sustained virologic response for chronic hepatitis C infection after 27 days of treatment with sofosbuvir and ribavirin. Open Forum Infect Dis 2014; doi: 10.1093/ofid/ofu013.
14. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A Inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146:736-43.e731.
15. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160:293-300.